๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Radiation therapy and 5-fluorouracil modulated by leucovorin for adenocarcinoma of the pancreas

โœ Scribed by David J. Schifeling; Andre A. Konski; John M. Howard; Ralph R. Dobelhower; Hollis W. Merrick; Roland T. Skeel

Book ID
112938857
Publisher
Springer US
Year
1992
Tongue
English
Weight
519 KB
Volume
12
Category
Article
ISSN
1941-6628

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Preoperative high-dose leucovorin/5-fluo
Preoperative high-dose leucovorin/5-fluorouracil and radiation therapy for unresectable rectal cancer
โœ Bruce D. Minsky; Nancy Kemeny; David P. Kelsen; Bonnie Reichman; Leonard Saltz; ๐Ÿ“‚ Article ๐Ÿ“… 1991 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 732 KB

Twenty patients with primary or recurrent unresectable rectal cancer limited to the pelvis were entered on a Phase I trial of preoperative pelvic radiation therapy (RT) (5040 cGy) and two cycles of combined high-dose leucovorin (LV) and 5fluorouracil (S-FU), followed by surgery and ten cycles of pos

Phase I study of 5-fluorouracil administ
Phase I study of 5-fluorouracil administered by protracted venous infusion, leucovorin, and pelvic radiation therapy
โœ James A. Martenson; Thomas G. Shanahan; Michael J. O'Connell; Charles D. Cobau; ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 63 KB ๐Ÿ‘ 2 views

## BACKGROUND. This study was designed to assess the toxicity of pelvic radiation therapy, 5-fluorouracil (5-FU) administered by protracted venous infusion, and leucovorin. ## METHODS. Pelvic radiation therapy consisted of 50.4 -54 gray (Gy) administered in 28 -30 fractions. Systemic treatment

The efficacy of preoperative 5-fluoroura
The efficacy of preoperative 5-fluorouracil, high-dose leucovorin, and sequential radiation therapy for unresectable rectal cancer
โœ Bruce D. Minsky; Joanne Frankel; Alfred M. Cohen; Warren E. Enker; Nancy Kemeny; ๐Ÿ“‚ Article ๐Ÿ“… 1993 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 744 KB

Background. The encouraging results seen in patients who received postoperative combined modality therapy in the adjuvant setting have prompted increased interest in preoperative combined modality therapy for patients with unresectable rectal cancer. The authors report the local control and survival